Brainstorm Financial Statements From 2010 to 2024
| GHDN Stock | EUR 2.69 0.00 0.00% |
Check Brainstorm Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brainstorm Cell's main balance sheet or income statement drivers, such as , as well as many indicators such as . Brainstorm financial statements analysis is a perfect complement when working with Brainstorm Cell Valuation or Volatility modules.
Brainstorm |
Brainstorm Cell Therapeutics Company Current Valuation Analysis
Brainstorm Cell's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Brainstorm Cell Current Valuation | 44.56 M |
Most of Brainstorm Cell's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brainstorm Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Brainstorm Cell Therapeutics has a Current Valuation of 44.56 M. This is 99.69% lower than that of the Healthcare sector and 99.04% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 99.73% higher than that of the company.
Brainstorm Cell Ther Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Brainstorm Cell's current stock value. Our valuation model uses many indicators to compare Brainstorm Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brainstorm Cell competition to find correlations between indicators driving Brainstorm Cell's intrinsic value. More Info.Brainstorm Cell Therapeutics is one of the top stocks in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brainstorm Cell's earnings, one of the primary drivers of an investment's value.About Brainstorm Cell Financial Statements
Brainstorm Cell stakeholders use historical fundamental indicators, such as Brainstorm Cell's revenue or net income, to determine how well the company is positioned to perform in the future. Although Brainstorm Cell investors may analyze each financial statement separately, they are all interrelated. For example, changes in Brainstorm Cell's assets and liabilities are reflected in the revenues and expenses on Brainstorm Cell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Brainstorm Cell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BRAINSTORM operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 31 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out the analysis of Brainstorm Cell Correlation against competitors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.